Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.49 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512957 | 0.94 | CYP3A4 (0.58) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL2512956 | 0.94 | CYP3A4 (0.58) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL14628568 | 0.90 | PRMT5 (0.48) | CYP3A4CYP2C9PRMT5WDR77 | |
| SCHEMBL14393475 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL14393337 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL14367296 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL14367294 | 0.89 | ADORA2A (0.52) | CYP3A4CYP2C9 | |
| SCHEMBL14367299 | 0.88 | CYP3A4 (0.48) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL14643253 | 0.87 | PRMT5 (0.46) | CYP3A4CYP2C9PRMT5WDR77 | |
| SCHEMBL14643344 | 0.87 | PRMT5 (0.46) | CYP3A4CYP2C9PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265222-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection | MERCK SHARP & DOHME CORP. | 2007-11-15 | — | — | US | disclosed |
| US-20070265222-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection | MERCK SHARP & DOHME CORP. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265222-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection | NSUN3, NSUN2, PNP | CYP3A4 1517/4885CYP2C9 1880/4885PRMT5 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.